Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept single-dose intramuscular rilpivirine long-acting monotherapy in treatment-naive HIV-1 infection
2008-006009-18Phase 2Suspended
- Sponsor
- Tibotec
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilpivirine in Human immunodeficiency virus infection type 1, sponsored by Tibotec. Primary endpoint: Plasma viral load level. Started Dec 2008; status: suspended.
02
Drugs
rilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2008-006009-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006009-18.